Advertisement

Molecular and Cellular Aspects of Mental Retardation in the Fragile X Syndrome: From Gene Mutation/s to Spine Dysmorphogenesis

  • Silvia De Rubeis
  • Esperanza Fernández
  • Andrea Buzzi
  • Daniele Di Marino
  • Claudia BagniEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (volume 970)

Abstract

The Fragile X syndrome (FXS) is the most frequent form of inherited mental retardation and also considered a monogenic cause of Autism Spectrum Disorder. FXS symptoms include neurodevelopmental delay, anxiety, hyperactivity, and autistic-like behavior. The disease is due to mutations or loss of the Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein abundant in the brain and gonads, the two organs mainly affected in FXS patients. FMRP has multiple functions in RNA metabolism, including mRNA decay, dendritic targeting of mRNAs, and protein synthesis. In neurons lacking FMRP, a wide array of mRNAs encoding proteins involved in synaptic structure and function are altered. As a result of this complex dysregulation, in the absence of FMRP, spine morphology and functioning is impaired. Consistently, model organisms for the study of the syndrome recapitulate the phenotype observed in FXS patients, such as dendritic spine anomalies and defects in learning.

Here, we review the fundamentals of genetic and clinical aspects of FXS, devoting a specific attention to ASD comorbidity and FXS-related diseases. We also review the current knowledge on FMRP functions through structural, molecular, and cellular findings. Finally, we discuss the neuroanatomical, electrophysiological, and behavioral defects caused by FMRP loss, as well as the current treatments able to partially revert some of the FXS abnormalities.

Keywords

FMR1 FMRP Fragile X Messenger ribonucleoparticles Spinogenesis 

Notes

Acknowledgments

This study was supported by Telethon, Compagnia di San Paolo, COFIN, FWO, and FP7 (SynSys). We are thankful to the Associazione Italiana Sindrome X Fragile (http://www.xfragile.net/).

References

  1. Abrahams, B. S., & Geschwind, D. H. (2008). Advances in autism genetics: On the threshold of a new neurobiology. Nature Reviews Genetics, 9, 341–355.PubMedCrossRefGoogle Scholar
  2. Allen, E. G., He, W., Yadav-Shah, M., & Sherman, S. L. (2004). A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Human Genetics, 114, 439–447.PubMedCrossRefGoogle Scholar
  3. Anderson, P., & Kedersha, N. (2006). RNA granules. The Journal of Cell Biology, 172, 803–808.PubMedCrossRefGoogle Scholar
  4. Antar, L. N., Afroz, R., Dictenberg, J. B., Carroll, R. C., & Bassell, G. J. (2004). Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. Journal of Neuroscience, 24, 2648–2655.PubMedCrossRefGoogle Scholar
  5. Antar, L. N., Dictenberg, J. B., Plociniak, M., Afroz, R., & Bassell, G. J. (2005). Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. Genes, Brain, and Behavior, 4, 350–359.PubMedCrossRefGoogle Scholar
  6. Antar, L. N., Li, C., Zhang, H., Carroll, R. C., & Bassell, G. J. (2006). Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Molecular and Cellular Neurosciences, 32, 37–48.PubMedCrossRefGoogle Scholar
  7. Ashley, C. T., Jr., Wilkinson, K. D., Reines, D., & Warren, S. T. (1993). FMR1 protein: Conserved RNP family domains and selective RNA binding. Science, 262, 563–566.PubMedCrossRefGoogle Scholar
  8. Bacalman, S., Farzin, F., Bourgeois, J. A., Cogswell, J., Goodlin-Jones, B. L., Gane, L. W., Grigsby, J., Leehey, M. A., Tassone, F., & Hagerman, R. J. (2006). Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: Newly described fronto-subcortical dementia. The Journal of Clinical Psychiatry, 67, 87–94.PubMedCrossRefGoogle Scholar
  9. Bagni, C., & Greenough, W. T. (2005). From mRNP trafficking to spine dysmorphogenesis: The roots of fragile X syndrome. Nature Reviews Neuroscience, 6, 376–387.PubMedCrossRefGoogle Scholar
  10. Baker, K. B., Wray, S. P., Ritter, R., Mason, S., Lanthorn, T. H., & Savelieva, K. V. (2010). Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes, Brain, and Behavior, 9, 562–574.PubMedGoogle Scholar
  11. Bardoni, B., Willemsen, R., Weiler, I. J., Schenck, A., Severijnen, L. A., Hindelang, C., Lalli, E., & Mandel, J. L. (2003). NUFIP1 (nuclear FMRP interacting protein 1) is a nucleocytoplasmic shuttling protein associated with active synaptoneurosomes. Experimental Cell Research, 289, 95–107.PubMedCrossRefGoogle Scholar
  12. Bassell, G. J., & Warren, S. T. (2008). Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron, 60, 201–214.PubMedCrossRefGoogle Scholar
  13. Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27, 370–377.PubMedCrossRefGoogle Scholar
  14. Belmonte, M. K., & Bourgeron, T. (2006). Fragile X syndrome and autism at the intersection of genetic and neural networks. Nature Neuroscience, 9, 1221–1225.PubMedCrossRefGoogle Scholar
  15. Berman, R. F., & Willemsen, R. (2009). Mouse models of fragile x-associated tremor ataxia. Journal of Investigative Medicine, 57, 837–841.PubMedGoogle Scholar
  16. Berry-Kravis, E. (2002). Epilepsy in fragile X syndrome. Developmental Medicine and Child Neurology, 44, 724–728.PubMedCrossRefGoogle Scholar
  17. Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. Journal of Medical Genetics, 46, 94–102.PubMedCrossRefGoogle Scholar
  18. Bramham, C. R., & Wells, D. G. (2007). Dendritic mRNA: Transport, translation and function. Nature Reviews Neuroscience, 8, 776–789.PubMedCrossRefGoogle Scholar
  19. Braun, K., & Segal, M. (2000). FMRP involvement in formation of synapses among cultured hippocampal neurons. Cerebral Cortex, 10, 1045–1052.PubMedCrossRefGoogle Scholar
  20. Brennan, F. X., Albeck, D. S., & Paylor, R. (2006). Fmr1 knockout mice are impaired in a leverpress escape/avoidance task. Genes, Brain, and Behavior, 5, 467–471.PubMedCrossRefGoogle Scholar
  21. Brouwer, J. R., Huizer, K., Severijnen, L. A., Hukema, R. K., Berman, R. F., Oostra, B. A., & Willemsen, R. (2008). CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. Journal of Neurochemistry, 107, 1671–1682.PubMedCrossRefGoogle Scholar
  22. Brown, V., Jin, P., Ceman, S., Darnell, J. C., O’Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., Darnell, R. B., & Warren, S. T. (2001). Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell, 107, 477–487.PubMedCrossRefGoogle Scholar
  23. Bucan, M., & Abel, T. (2002). The mouse: Genetics meets behaviour. Nature Reviews Genetics, 3, 114–123.PubMedCrossRefGoogle Scholar
  24. Brown, M. R., Kronengold, J., Gazula, V.-R., Chen, Y., Strumbos, J. G., Sigworth, F. J., Navaratnam, D., & Kaczmarek. L. K., (2010). Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nature Neuroscience Vol 13 (7) Jul 2010.Google Scholar
  25. Bakker, C. (1994). Fmr1 knockout mice: A model to study fragile X mental retardation. The Dutch-Belgian fragile X consortium. Cell, 78, 23–33.Google Scholar
  26. Capocchi, G., Zampolini, M., & Larson, J. (1992). Theta burst stimulation is optimal for induction of LTP at both apical and basal dendritic synapses on hippocampal CA1 neurons. Brain Research, 591, 332–336.PubMedCrossRefGoogle Scholar
  27. Ceman, S., O’Donnell, W. T., Reed, M., Patton, S., Pohl, J., & Warren, S. T. (2003). Phosphorylation influences the translation state of FMRP-associated polyribosomes. Human Molecular Genetics, 12, 3295–3305.PubMedCrossRefGoogle Scholar
  28. Centonze, D., Rossi, S., Mercaldo, V., Napoli, I., Ciotti, M. T., De Chiara, V., Musella, A., Prosperetti, C., Calabresi, P., Bernardi, G., & Bagni, C. (2008). Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biological Psychiatry, 63, 963–973.PubMedCrossRefGoogle Scholar
  29. Chen, L., & Toth, M. (2001). Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience, 103, 1043–1050.PubMedCrossRefGoogle Scholar
  30. Cheever, A., Ceman, S., (2009). Phosphorylation of FMRP inhibits association with Dicer. RNA. 15(3):362–6.PubMedCrossRefGoogle Scholar
  31. Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, P., Kollaros, M., Gertner, M. J., Woo, N. H., Tranfaglia, M. R., Bear, M. F., Zukin, R. S., McDonald, T. V., Jongens, T. A., & McBride, S. M. (2010). Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Research, 1380, 106–119.PubMedCrossRefGoogle Scholar
  32. Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997). Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proceedings of the National Academy of Sciences of the United States of America, 94, 5401–5404.PubMedCrossRefGoogle Scholar
  33. Cornish, K. M., Li, L., Kogan, C. S., Jacquemont, S., Turk, J., Dalton, A., Hagerman, R. J., & Hagerman, P. J. (2008). Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex, 44, 628–636.PubMedCrossRefGoogle Scholar
  34. Cruz-Martin, A., Crespo, M., & Portera-Cailliau, C. (2010). Delayed stabilization of dendritic spines in fragile X mice. Journal of Neuroscience, 30, 7793–7803.PubMedCrossRefGoogle Scholar
  35. Curia, G., Papouin, T., Seguela, P., & Avoli, M. (2009). Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cerebral Cortex, 19, 1515–1520.PubMedCrossRefGoogle Scholar
  36. D’Hooge, R., Nagels, G., Franck, F., Bakker, C. E., Reyniers, E., Storm, K., Kooy, R. F., Oostra, B. A., Willems, P. J., & De Deyn, P. P. (1997). Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience, 76, 367–376.PubMedCrossRefGoogle Scholar
  37. D’Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., & Kooy, R. F. (2006). Decreased expression of the GABAA receptor in fragile X syndrome. Brain Research, 1121, 238–245.PubMedCrossRefGoogle Scholar
  38. Dahlhaus, R., & El-Husseini, A. (2010). Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behavioural Brain Research, 208, 96–105.PubMedCrossRefGoogle Scholar
  39. Darnell, J. C., Jensen, K. B., Jin, P., Brown, V., Warren, S. T., & Darnell, R. B. (2001). Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell, 107, 489–499.PubMedCrossRefGoogle Scholar
  40. Davidovic, L., Jaglin, X. H., Lepagnol-Bestel, A. M., Tremblay, S., Simonneau, M., Bardoni, B., & Khandjian, E. W. (2007). The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. Human Molecular Genetics, 16, 3047–3058.PubMedCrossRefGoogle Scholar
  41. De Boulle, K., Verkerk, A. J., Reyniers, E., Vits, L., Hendrickx, J., Van Roy, B., Van den Bos, F., de Graaff, E., Oostra, B. A., & Willems, P. J. (1993). A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nature Genetics, 3, 31–35.PubMedCrossRefGoogle Scholar
  42. De Rubeis, S., & Bagni, C. (2010). Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability. Molecular and Cellular Neurosciences, 43, 43–50.PubMedCrossRefGoogle Scholar
  43. de Vrij, F. M., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008). Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiology of Disease, 31, 127–132.PubMedCrossRefGoogle Scholar
  44. den Broeder, M. J., van der Linde, H., Brouwer, J. R., Oostra, B. A., Willemsen, R., & Ketting, R. F. (2009). Generation and characterization of FMR1 knockout zebrafish. PLoS One, 4, e7910.CrossRefGoogle Scholar
  45. Dictenberg, J. B., Swanger, S. A., Antar, L. N., Singer, R. H., & Bassell, G. J. (2008). A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Developmental Cell, 14, 926–939.PubMedCrossRefGoogle Scholar
  46. Dobkin, C., Rabe, A., Dumas, R., El Idrissi, A., Haubenstock, H., & Brown, W. T. (2000). Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience, 100, 423–429.PubMedCrossRefGoogle Scholar
  47. Dockendorff, T. C., Su, H. S., McBride, S. M., Yang, Z., Choi, C. H., Siwicki, K. K., Sehgal, A., & Jongens, T. A. (2002). Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron, 34, 973–984.PubMedCrossRefGoogle Scholar
  48. Dolen, G., Carpenter, R. L., Ocain, T. D., & Bear, M. F. (2010). Mechanism-based approaches to treating fragile X. Pharmacology and Therapeutics, 127, 78–93.PubMedCrossRefGoogle Scholar
  49. Dolen, G., Osterweil, E., Rao, B. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007). Correction of fragile X syndrome in mice. Neuron, 56, 955–962.PubMedCrossRefGoogle Scholar
  50. Eadie, B. D., Cushman, J., Kannangara, T. S., Fanselow, M. S., & Christie, B. R. (2010). NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice. Hippocampus. 3 NOV 2010, DOI: 10.1002/hipo.20890.Google Scholar
  51. Eberhart, D. E., Malter, H. E., Feng, Y., & Warren, S. T. (1996). The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Human Molecular Genetics, 5, 1083–1091.PubMedCrossRefGoogle Scholar
  52. Edbauer, D., Neilson, J. R., Foster, K. A., Wang, C. F., Seeburg, D. P., Batterton, M. N., Tada, T., Dolan, B. M., Sharp, P. A., & Sheng, M. (2010). Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron, 65, 373–384.PubMedCrossRefGoogle Scholar
  53. El Idrissi, A., Boukarrou, L., Dokin, C., & Brown, W. T. (2009). Taurine improves congestive functions in a mouse model of fragile X syndrome. Advances in Experimental Medicine and Biology, 643, 191–198.PubMedCrossRefGoogle Scholar
  54. El Idrissi, A., Ding, X. H., Scalia, J., Trenkner, E., Brown, W. T., & Dobkin, C. (2005). Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neuroscience Letters, 377, 141–146.PubMedCrossRefGoogle Scholar
  55. Entezam, A., Biacsi, R., Orrison, B., Saha, T., Hoffman, G. E., Grabczyk, E., Nussbaum, R. L., & Usdin, K. (2007). Regional FMRP deficits and large repeat expansions into the full mutation range in a new fragile X premutation mouse model. Gene, 395, 125–134.PubMedCrossRefGoogle Scholar
  56. Farzin, F., Perry, H., Hessl, D., Loesch, D., Cohen, J., Bacalman, S., Gane, L., Tassone, F., Hagerman, P., & Hagerman, R. (2006). Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. Journal of Developmental and Behavioral Pediatrics, 27, S137–144.PubMedCrossRefGoogle Scholar
  57. Feng, Y., Zhang, F., Lokey, L. K., Chastain, J. L., Lakkis, L., Eberhart, D., & Warren, S. T. (1995). Translational suppression by trinucleotide repeat expansion at FMR1. Science, 268, 731–734.PubMedCrossRefGoogle Scholar
  58. Fernandez-Carvajal, I., Lopez Posadas, B., Pan, R., Raske, C., Hagerman, P. J., & Tassone, F. (2009). Expansion of an FMR1 grey-zone allele to a full mutation in two generations. Journal of Molecular Diagnostics, 11, 306–310.PubMedCrossRefGoogle Scholar
  59. Ferrari, F., Mercaldo, V., Piccoli, G., Sala, C., Cannata, S., Achsel, T., & Bagni, C. (2007). The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Molecular and Cellular Neurosciences, 34, 343–354.PubMedCrossRefGoogle Scholar
  60. Flavell, S. W., & Greenberg, M. E. (2008). Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annual Review of Neuroscience, 31, 563–590.PubMedCrossRefGoogle Scholar
  61. Fombonne, E. (2005). Epidemiology of autistic disorder and other pervasive developmental disorders. The Journal of Clinical Psychiatry, 66(Suppl 10), 3–8.PubMedGoogle Scholar
  62. Fowler, C. E., Aryal, P., Suen, K. F., & Slesinger, P. A. (2007). Evidence for association of GABA(B) receptors with Kir3 channels and regulators of G protein signalling (RGS4) proteins. The Journal of Physiology, 580, 51–65.PubMedCrossRefGoogle Scholar
  63. Frankland, P. W., Wang, Y., Rosner, B., Shimizu, T., Balleine, B. W., Dykens, E. M., Ornitz, E. M., & Silva, A. J. (2004). Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Molecular Psychiatry, 9, 417–425.PubMedCrossRefGoogle Scholar
  64. Galvez, R., Gopal, A. R., & Greenough, W. T. (2003). Somatosensory cortical barrel dendritic abnormalities in a mouse model of the fragile X mental retardation syndrome. Brain Research, 971, 83–89.PubMedCrossRefGoogle Scholar
  65. Galvez, R., & Greenough, W. T. (2005). Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. American Journal of Medical Genetics A, 135, 155–160.CrossRefGoogle Scholar
  66. Gantois, I., Vandesompele, J., Speleman, F., Reyniers, E., D’Hooge, R., Severijnen, L. A., Willemsen, R., Tassone, F., & Kooy, R. F. (2006). Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiology of Disease, 21, 346–357.PubMedCrossRefGoogle Scholar
  67. Garber, K. B., Visootsak, J., & Warren, S. T. (2008). Fragile X syndrome. European Journal of Human Genetics, 16, 666–672.PubMedCrossRefGoogle Scholar
  68. Garcia-Nonell, C., Ratera, E. R., Harris, S., Hessl, D., Ono, M. Y., Tartaglia, N., Marvin, E., Tassone, F., & Hagerman, R. J. (2008). Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. American Journal of Medical Genetics A, 146A, 1911–1916.CrossRefGoogle Scholar
  69. Gedeon, A. K., Baker, E., Robinson, H., Partington, M. W., Gross, B., Manca, A., Korn, B., Poustka, A., Yu, S., Sutherland, G. R., et al. (1992). Fragile X syndrome without CCG amplification has an FMR1 deletion. Nature Genetics, 1, 341–344.PubMedCrossRefGoogle Scholar
  70. Gladding, C. M., Fitzjohn, S. M., & Molnar, E. (2009). Metabotropic glutamate receptor-mediated long-term depression: Molecular mechanisms. Pharmacological Reviews, 61, 395–412.PubMedCrossRefGoogle Scholar
  71. Godfraind, J. M., Reyniers, E., De Boulle, K., D’Hooge, R., De Deyn, P. P., Bakker, C. E., Oostra, B. A., Kooy, R. F., & Willems, P. J. (1996). Long-term potentiation in the hippocampus of fragile X knockout mice. American Journal of Medical Genetics, 64, 246–251.PubMedCrossRefGoogle Scholar
  72. Greco, C. M., Berman, R. F., Martin, R. M., Tassone, F., Schwartz, P. H., Chang, A., Trapp, B. D., Iwahashi, C., Brunberg, J., Grigsby, J., Hessl, D., Becker, E. J., Papazian, J., Leehey, M. A., Hagerman, R. J., & Hagerman, P. J. (2006). Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain, 129, 243–255.PubMedCrossRefGoogle Scholar
  73. Greco, C. M., Hagerman, R. J., Tassone, F., Chudley, A. E., Del Bigio, M. R., Jacquemont, S., Leehey, M., & Hagerman, P. J. (2002). Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain, 125, 1760–1771.PubMedCrossRefGoogle Scholar
  74. Grishin, N. V. (2001). KH domain: One motif, two folds. Nucleic Acids Research, 29, 638–643.PubMedCrossRefGoogle Scholar
  75. Gross, C., Nakamoto, M., Yao, X., Chan, C. B., Yim, S. Y., Ye, K., Warren, S. T., & Bassell, G. J. (2010). Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. Journal of Neuroscience, 30, 10624–10638.PubMedCrossRefGoogle Scholar
  76. Grossman, A. W., Aldridge, G. M., Lee, K. J., Zeman, M. K., Jun, C. S., Azam, H. S., Arii, T., Imoto, K., Greenough, W. T., & Rhyu, I. J. (2010). Developmental characteristics of dendritic spines in the dentate gyrus of Fmr1 knockout mice. Brain Research, 1355, 221–227.PubMedCrossRefGoogle Scholar
  77. Gruss, M., & Braun, K. (2001). Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: A putative animal model of the human fragile X mental retardation syndrome. Neural Plasticity, 8, 285–298.PubMedCrossRefGoogle Scholar
  78. Hagerman, R. J., & Hagerman, P. J. (2002). The fragile X premutation: Into the phenotypic fold. Current Opinion in Genetics and Development, 12, 278–283.PubMedCrossRefGoogle Scholar
  79. Hagerman, P. J., & Hagerman, R. J. (2007). Fragile X-associated tremor/ataxia syndrome – An older face of the fragile X gene. Nature Clinical Practice Neurology, 3, 107–112.PubMedCrossRefGoogle Scholar
  80. Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., Grigsby, J., Gage, B., & Hagerman, P. J. (2001). Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology, 57, 127–130.PubMedCrossRefGoogle Scholar
  81. Hallahan, B. P., Craig, M. C., Toal, F., Daly, E. M., Moore, C. J., Ambikapathy, A., Robertson, D., Murphy, K. C., & Murphy, D. G. (2010). In vivo brain anatomy of adult males with fragile X syndrome: an MRI study. NeuroImage, 54(1):16–24.Google Scholar
  82. Harris, S. W., Hessl, D., Goodlin-Jones, B., Ferranti, J., Bacalman, S., Barbato, I., Tassone, F., Hagerman, P. J., Herman, H., & Hagerman, R. J. (2008). Autism profiles of males with fragile X syndrome. American Journal on Mental Retardation, 113, 427–438.PubMedCrossRefGoogle Scholar
  83. Hatton, D. D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D. B., Jr., Roberts, J., & Mirrett, P. (2006). Autistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP. American Journal of Medical Genetics A, 140A, 1804–1813.CrossRefGoogle Scholar
  84. Hayashi, M. L., Rao, B. S., Seo, J. S., Choi, H. S., Dolan, B. M., Choi, S. Y., Chattarji, S., & Tonegawa, S. (2007). Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proceedings of the National Academy of Sciences of the United States of America, 104, 11489–11494.PubMedCrossRefGoogle Scholar
  85. Hernandez, R. N., Feinberg, R. L., Vaurio, R., Passanante, N. M., Thompson, R. E., & Kaufmann, W. E. (2009). Autism spectrum disorder in fragile X syndrome: A longitudinal evaluation. American Journal of Medical Genetics A, 149A, 1125–1137.CrossRefGoogle Scholar
  86. Holt, C. E., & Bullock, S. L. (2009). Subcellular mRNA localization in animal cells and why it matters. Science, 326, 1212–1216.PubMedCrossRefGoogle Scholar
  87. Holtmaat, A., & Svoboda, K. (2009). Experience-dependent structural synaptic plasticity in the mammalian brain. Nature Reviews Neuroscience, 10, 647–658.PubMedCrossRefGoogle Scholar
  88. Hou, L., Antion, M. D., Hu, D., Spencer, C. M., Paylor, R., & Klann, E. (2006). Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron, 51, 441–454.PubMedCrossRefGoogle Scholar
  89. Hou, L., & Klann, E. (2004). Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. Journal of Neuroscience, 24, 6352–6361.PubMedCrossRefGoogle Scholar
  90. Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proceedings of the National Academy of Sciences of the United States of America, 99, 7746–7750.PubMedCrossRefGoogle Scholar
  91. Huber, K. M., Kayser, M. S., & Bear, M. F. (2000). Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science, 288, 1254–1257.PubMedCrossRefGoogle Scholar
  92. Inoue, S., Shimoda, M., Nishinokubi, I., Siomi, M. C., Okamura, M., Nakamura, A., Kobayashi, S., Ishida, N., & Siomi, H. (2002). A role for the Drosophila fragile X-related gene in circadian output. Current Biology, 12, 1331–1335.PubMedCrossRefGoogle Scholar
  93. Irwin, S. A., Idupulapati, M., Gilbert, M. E., Harris, J. B., Chakravarti, A. B., Rogers, E. J., Crisostomo, R. A., Larsen, B. P., Mehta, A., Alcantara, C. J., Patel, B., Swain, R. A., Weiler, I. J., Oostra, B. A., & Greenough, W. T. (2002). Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. American Journal of Medical Genetics, 111, 140–146.PubMedCrossRefGoogle Scholar
  94. Irwin, S. A., Patel, B., Idupulapati, M., Harris, J. B., Crisostomo, R. A., Larsen, B. P., Kooy, F., Willems, P. J., Cras, P., Kozlowski, P. B., Swain, R. A., Weiler, I. J., & Greenough, W. T. (2001). Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: A quantitative examination. American Journal of Medical Genetics, 98, 161–167.PubMedCrossRefGoogle Scholar
  95. Ishizuka, A., Siomi, M. C., & Siomi, H. (2002). A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes & Development, 16, 2497–2508.CrossRefGoogle Scholar
  96. Iwahashi, C. K., Yasui, D. H., An, H. J., Greco, C. M., Tassone, F., Nannen, K., Babineau, B., Lebrilla, C. B., Hagerman, R. J., & Hagerman, P. J. (2006). Protein composition of the intranuclear inclusions of FXTAS. Brain, 129, 256–271.PubMedCrossRefGoogle Scholar
  97. Jacquemont, S., Hagerman, R. J., Hagerman, P. J., & Leehey, M. A. (2007). Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: Two faces of FMR1. Lancet Neurology, 6, 45–55.PubMedCrossRefGoogle Scholar
  98. Jin, P., Duan, R., Qurashi, A., Qin, Y., Tian, D., Rosser, T. C., Liu, H., Feng, Y., & Warren, S. T. (2007). Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron, 55, 556–564.PubMedCrossRefGoogle Scholar
  99. Johnson, E. M., Kinoshita, Y., Weinreb, D. B., Wortman, M. J., Simon, R., Khalili, K., Winckler, B., & Gordon, J. (2006). Role of Pur alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. Journal of Neuroscience Research, 83, 929–943.PubMedCrossRefGoogle Scholar
  100. Kanai, Y., Dohmae, N., & Hirokawa, N. (2004). Kinesin transports RNA: Isolation and characterization of an RNA-transporting granule. Neuron, 43, 513–525.PubMedCrossRefGoogle Scholar
  101. Kao, D. I., Aldridge, G. M., Weiler, I. J., & Greenough, W. T. (2010). Altered mRNA transport, docking, and protein translation in neurons lacking fragile X mental retardation protein. Proceedings of the National Academy of Sciences of the United States of America, 107, 15601–15606.PubMedCrossRefGoogle Scholar
  102. Kaufmann, W. E., Cohen, S., Sun, H. T., & Ho, G. (2002). Molecular phenotype of fragile X syndrome: FMRP, FXRPs, and protein targets. Microscopy Research and Technique, 57, 135–144.PubMedCrossRefGoogle Scholar
  103. Kenneson, A., Zhang, F., Hagedorn, C. H., & Warren, S. T. (2001). Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Human Molecular Genetics, 10, 1449–1454.PubMedCrossRefGoogle Scholar
  104. Khandjian, E. W., Fortin, A., Thibodeau, A., Tremblay, S., Cote, F., Devys, D., Mandel, J. L., & Rousseau, F. (1995). A heterogeneous set of FMR1 proteins is widely distributed in mouse tissues and is modulated in cell culture. Human Molecular Genetics, 4, 783–789.PubMedCrossRefGoogle Scholar
  105. Khandjian, E. W., Huot, M. E., Tremblay, S., Davidovic, L., Mazroui, R., & Bardoni, B. (2004). Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proceedings of the National Academy of Sciences of the United States of America, 101, 13357–13362.PubMedCrossRefGoogle Scholar
  106. Kindler, S., Rehbein, M., Classen, B., Richter, D., Böckers, TM., (2004). Distinct spatiotemporal expression of SAPAP transcripts in the developing rat brain: a novel dendritically localized mRNA. Brain Res Mol Brain Res. 126(1):14–21.Google Scholar
  107. Koekkoek, S. K., Yamaguchi, K., Milojkovic, B. A., Dortland, B. R., Ruigrok, T. J., Maex, R., De Graaf, W., Smit, A. E., VanderWerf, F., Bakker, C. E., Willemsen, R., Ikeda, T., Kakizawa, S., Onodera, K., Nelson, D. L., Mientjes, E., Joosten, M., De Schutter, E., Oostra, B. A., Ito, M., & De Zeeuw, C. I. (2005). Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron, 47, 339–352.PubMedCrossRefGoogle Scholar
  108. Kooy, R. F. (2003). Of mice and the fragile X syndrome. Trends in Genetics, 19, 148–154.PubMedCrossRefGoogle Scholar
  109. Kooy, R. F., D’Hooge, R., Reyniers, E., Bakker, C. E., Nagels, G., De Boulle, K., Storm, K., Clincke, G., De Deyn, P. P., Oostra, B. A., & Willems, P. J. (1996). Transgenic mouse model for the fragile X syndrome. American Journal of Medical Genetics, 64, 241–245.PubMedCrossRefGoogle Scholar
  110. Laggerbauer, B., Ostareck, D., Keidel, E. M., Ostareck-Lederer, A., & Fischer, U. (2001). Evidence that fragile X mental retardation protein is a negative regulator of translation. Human Molecular Genetics, 10, 329–338.PubMedCrossRefGoogle Scholar
  111. Larson, J., Jessen, R. E., Kim, D., Fine, A. K., & du Hoffmann, J. (2005). Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. Journal of Neuroscience, 25, 9460–9469.PubMedCrossRefGoogle Scholar
  112. Lauterborn, J. C., Rex, C. S., Kramar, E., Chen, L. Y., Pandyarajan, V., Lynch, G., & Gall, C. M. (2007). Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. Journal of Neuroscience, 27, 10685–10694.PubMedCrossRefGoogle Scholar
  113. Li, J., Pelletier, M. R., Perez Velazquez, J. L., & Carlen, P. L. (2002). Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Molecular and Cellular Neurosciences, 19, 138–151.PubMedCrossRefGoogle Scholar
  114. Li, Z., Zhang, Y., Ku, L., Wilkinson, K. D., Warren, S. T., & Feng, Y. (2001). The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Research, 29, 2276–2283.PubMedCrossRefGoogle Scholar
  115. Linder, B., Plottner, O., Kroiss, M., Hartmann, E., Laggerbauer, B., Meister, G., Keidel, E., & Fischer, U. (2008). Tdrd3 is a novel stress granule-associated protein interacting with the fragile-X syndrome protein FMRP. Human Molecular Genetics, 17, 3236–3246.PubMedCrossRefGoogle Scholar
  116. Liu, Z. H., Chuang, D. M., Smith, C. B., Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol. 2011 Jun;14(5):618-30. Epub 2010 May 25.Google Scholar
  117. Liu, Z. H., & Smith, C. B. (2009). Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neuroscience Letters, 454, 62–66.PubMedCrossRefGoogle Scholar
  118. Lu, R., Wang, H., Liang, Z., Ku, L., O’Donnell, W. T., Li, W., Warren, S. T., & Feng, Y. (2004). The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proceedings of the National Academy of Sciences of the United States of America, 101, 15201–15206.PubMedCrossRefGoogle Scholar
  119. Massey, P. V., & Bashir, Z. I. (2007). Long-term depression: Multiple forms and implications for brain function. Trends in Neurosciences, 30, 176–184.PubMedCrossRefGoogle Scholar
  120. McNaughton, C. H., Moon, J., Strawderman, M. S., Maclean, K. N., Evans, J., & Strupp, B. J. (2008). Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behavioral Neuroscience, 122, 293–300.PubMedCrossRefGoogle Scholar
  121. Meijer, H., de Graaff, E., Merckx, D. M., Jongbloed, R. J., de Die-Smulders, C. E., Engelen, J. J., Fryns, J. P., Curfs, P. M., & Oostra, B. A. (1994). A deletion of 1.6 kb proximal to the CGG repeat of the FMR1 gene causes the clinical phenotype of the fragile X syndrome. Human Molecular Genetics, 3, 615–620.PubMedCrossRefGoogle Scholar
  122. Menon, R. P., Gibson, T. J., & Pastore, A. (2004). The C terminus of fragile X mental retardation protein interacts with the multi-domain Ran-binding protein in the microtubule-organising centre. Journal of Molecular Biology, 343, 43–53.PubMedCrossRefGoogle Scholar
  123. Meredith, R. M., Holmgren, C. D., Weidum, M., Burnashev, N., & Mansvelder, H. D. (2007). Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. Neuron, 54, 627–638.PubMedCrossRefGoogle Scholar
  124. Mientjes, E. J., Nieuwenhuizen, I., Kirkpatrick, L., Zu, T., Hoogeveen-Westerveld, M., Severijnen, L., Rife, M., Willemsen, R., Nelson, D. L., & Oostra, B. A. (2006). The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiology of Disease, 21, 549–555.PubMedCrossRefGoogle Scholar
  125. Mila, M., Castellvi-Bel, S., Sanchez, A., Barcelo, A., Badenas, C., Mallolas, J., & Estivill, X. (2000). Rare variants in the promoter of the fragile X syndrome gene (FMR1). Molecular and Cellular Probes, 14, 115–119.PubMedCrossRefGoogle Scholar
  126. Min, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009). Elevated glycogen synthase kinase-3 activity in fragile X mice: Key metabolic regulator with evidence for treatment potential. Neuropharmacology, 56, 463–472.PubMedCrossRefGoogle Scholar
  127. Mines, M. A., Yuskaitis, C. J., King, M. K., Beurel, E., & Jope, R. S. (2010). GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One, 5, e9706.PubMedCrossRefGoogle Scholar
  128. Mineur, Y. S., Huynh, L. X., & Crusio, W. E. (2006). Social behavior deficits in the Fmr1 mutant mouse. Behavioural Brain Research, 168, 172–175.PubMedCrossRefGoogle Scholar
  129. Mineur, Y. S., Sluyter, F., de Wit, S., Oostra, B. A., & Crusio, W. E. (2002). Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus, 12, 39–46.PubMedCrossRefGoogle Scholar
  130. Miyashiro, K. Y., Beckel-Mitchener, A., Purk, T. P., Becker, K. G., Barret, T., Liu, L., Carbonetto, S., Weiler, I. J., Greenough, W. T., & Eberwine, J. (2003). RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron, 37, 417–431.PubMedCrossRefGoogle Scholar
  131. Monzo, K., Papoulas, O., Cantin, G. T., Wang, Y., Yates, J. R., 3rd, & Sisson, J. C. (2006). Fragile X mental retardation protein controls trailer hitch expression and cleavage furrow formation in Drosophila embryos. Proceedings of the National Academy of Sciences of the United States of America, 103, 18160–18165.PubMedCrossRefGoogle Scholar
  132. Moon, J., Ota, K. T., Driscoll, L. L., Levitsky, D. A., & Strupp, B. J. (2008). A mouse model of fragile X syndrome exhibits heightened arousal and/or emotion following errors or reversal of contingencies. Developmental Psychobiology, 50, 473–485.PubMedCrossRefGoogle Scholar
  133. Morales, J., Hiesinger, P. R., Schroeder, A. J., Kume, K., Verstreken, P., Jackson, F. R., Nelson, D. L., & Hassan, B. A. (2002). Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron, 34, 961–972.PubMedCrossRefGoogle Scholar
  134. Moss, J., & Howlin, P. (2009). Autism spectrum disorders in genetic syndromes: Implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. Journal of Intellectual Disability Research, 53, 852–873.PubMedCrossRefGoogle Scholar
  135. Muddashetty, R. S., Kelic, S., Gross, C., Xu, M., & Bassell, G. J. (2007). Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. Journal of Neuroscience, 27, 5338–5348.PubMedCrossRefGoogle Scholar
  136. Musco, G., Stier, G., Joseph, C., Castiglione Morelli, M. A., Nilges, M., Gibson, T. J., & Pastore, A. (1996). Three-dimensional structure and stability of the KH domain: Molecular insights into the fragile X syndrome. Cell, 85, 237–245.PubMedCrossRefGoogle Scholar
  137. Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R., & Oostra, B. A. (2000). Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia, 41, 19–23.PubMedCrossRefGoogle Scholar
  138. Musumeci, S. A., Hagerman, R. J., Ferri, R., Bosco, P., Dalla Bernardina, B., Tassinari, C. A., De Sarro, G. B., & Elia, M. (1999). Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia, 40, 1092–1099.PubMedCrossRefGoogle Scholar
  139. Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., Witke, W., Costa-Mattioli, M., Sonenberg, N., Achsel, T., & Bagni, C. (2008). The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell, 134, 1042–1054.PubMedCrossRefGoogle Scholar
  140. Narayanan, U., Nalavadi, V., Nakamoto, M., Pallas, D. C., Ceman, S., Bassell, G. J., & Warren, S. T. (2007). FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. Journal of Neuroscience, 27, 14349–14357.PubMedCrossRefGoogle Scholar
  141. Nielsen, D. M., Derber, W. J., McClellan, D. A., & Crnic, L. S. (2002a). Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Research, 927, 8–17.PubMedCrossRefGoogle Scholar
  142. Nielsen, D. M., Evans, J. J., Derber, W. J., Johnston, K. A., Laudenslager, M. L., Crnic, L. S., & Maclean, K. N. (2009). Mouse model of fragile X syndrome: Behavioral and hormonal response to stressors. Behavioral Neuroscience, 123, 677–686.PubMedCrossRefGoogle Scholar
  143. Nielsen, P. R., Nietlispach, D., Mott, H. R., Callaghan, J., Bannister, A., Kouzarides, T., Murzin, A. G., Murzina, N. V., & Laue, E. D. (2002b). Structure of the HP1 chromodomain bound to histone H3 methylated at lysine 9. Nature, 416, 103–107.PubMedCrossRefGoogle Scholar
  144. Nimchinsky, E. A., Oberlander, A. M., & Svoboda, K. (2001). Abnormal development of dendritic spines in FMR1 knock-out mice. Journal of Neuroscience, 21, 5139–5146.PubMedGoogle Scholar
  145. Nosyreva, E. D., & Huber, K. M. (2006). Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. Journal of Neurophysiology, 95, 3291–3295.PubMedCrossRefGoogle Scholar
  146. O’Donnell, W. T., & Warren, S. T. (2002). A decade of molecular studies of fragile X syndrome. Annual Review of Neuroscience, 25, 315–338.PubMedCrossRefGoogle Scholar
  147. Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G., & Huntsman, M. M. (2010). Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. Journal of Neuroscience, 30, 9929–9938.PubMedCrossRefGoogle Scholar
  148. Pacey, L. K., Doss, L., Cifelli, C., der Kooy, D. V., Heximer, S. P., & Hampson, D. R. (2011). Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. Molecular and Cellular Neurosciences, 46(3), 563–72.PubMedCrossRefGoogle Scholar
  149. Pacey, L. K., Heximer, S. P., & Hampson, D. R. (2009). Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Molecular Pharmacology, 76, 18–24.PubMedCrossRefGoogle Scholar
  150. Pan, F., Aldridge, G. M., Greenough, W. T., & Gan, W. B. (2010). Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America, 107, 17768–17773.PubMedCrossRefGoogle Scholar
  151. Papoulas, O., Monzo, K. F., Cantin, G. T., Ruse, C., Yates, J. R., 3rd, Ryu, Y. H., & Sisson, J. C. (2010). dFMRP and Caprin, translational regulators of synaptic plasticity, control the cell cycle at the Drosophila mid-blastula transition. Development, 137, 4201–4209.PubMedCrossRefGoogle Scholar
  152. Paradee, W., Melikian, H. E., Rasmussen, D. L., Kenneson, A., Conn, P. J., & Warren, S. T. (1999). Fragile X mouse: Strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience, 94, 185–192.PubMedCrossRefGoogle Scholar
  153. Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurology, 10, 91.PubMedCrossRefGoogle Scholar
  154. Park, S., Park, J. M., Kim, S., Kim, J. A., Shepherd, J. D., Smith-Hicks, C. L., Chowdhury, S., Kaufmann, W., Kuhl, D., Ryazanov, A. G., Huganir, R. L., Linden, D. J., Worley, P. F., (2008). Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron. 59(1):70–83.Google Scholar
  155. Paylor, R., Yuva-Paylor, L. A., Nelson, D. L., & Spencer, C. M. (2008). Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene. Behavioral Neuroscience, 122, 1371–1377.PubMedCrossRefGoogle Scholar
  156. Peier, A. M., McIlwain, K. L., Kenneson, A., Warren, S. T., Paylor, R., & Nelson, D. L. (2000). (Over)correction of FMR1 deficiency with YAC transgenics: Behavioral and physical features. Human Molecular Genetics, 9, 1145–1159.PubMedCrossRefGoogle Scholar
  157. Pfeiffer, B. E., & Huber, K. M. (2007). Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. Journal of Neuroscience, 27, 3120–3130.PubMedCrossRefGoogle Scholar
  158. Pfeiffer, B. E., Zang, T., Wilkerson, J. R., Taniguchi, M., Maksimova, M. A., Smith, L. N., Cowan, C. W., & Huber, K. M. (2010). Fragile X mental retardation protein is required for synapse elimination by the activity-dependent transcription factor MEF2. Neuron, 66, 191–197.PubMedCrossRefGoogle Scholar
  159. Portera-Cailliau, C., Pan, D. T., & Yuste, R. (2003). Activity-regulated dynamic behavior of early dendritic protrusions: Evidence for different types of dendritic filopodia. Journal of Neuroscience, 23, 7129–7142.PubMedGoogle Scholar
  160. Primerano, B., Tassone, F., Hagerman, R. J., Hagerman, P., Amaldi, F., & Bagni, C. (2002). Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA, 8, 1482–1488.PubMedGoogle Scholar
  161. Purpura, D. P. (1974). Dendritic spine “dysgenesis” and mental retardation. Science, 186, 1126–1128.PubMedCrossRefGoogle Scholar
  162. Qiu, L. F., Lu, T. J., Hu, X. L., Yi, Y. H., Liao, W. P., & Xiong, Z. Q. (2009). Limbic epileptogenesis in a mouse model of fragile X syndrome. Cerebral Cortex, 19, 1504–1514.PubMedCrossRefGoogle Scholar
  163. Ramos, A., Hollingworth, D., Adinolfi, S., Castets, M., Kelly, G., Frenkiel, T. A., Bardoni, B., & Pastore, A. (2006). The structure of the N-terminal domain of the fragile X mental retardation protein: A platform for protein–protein interaction. Structure, 14, 21–31.PubMedCrossRefGoogle Scholar
  164. Reiss, A. L., Abrams, M. T., Greenlaw, R., Freund, L., & Denckla, M. B. (1995). Neurodevelopmental effects of the FMR-1 full mutation in humans. Nature Medicine, 1, 159–167.PubMedCrossRefGoogle Scholar
  165. Restivo, L., Ferrari, F., Passino, E., Sgobio, C., Bock, J., Oostra, B. A., Bagni, C., & Ammassari-Teule, M. (2005). Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America, 102, 11557–11562.PubMedCrossRefGoogle Scholar
  166. Ronesi, J. A., & Huber, K. M. (2008). Metabotropic glutamate receptors and fragile X mental retardation protein: Partners in translational regulation at the synapse. Science Signaling, 1, pe6.PubMedCrossRefGoogle Scholar
  167. Rudelli, R. D., Brown, W. T., Wisniewski, K., Jenkins, E. C., Laure-Kamionowska, M., Connell, F., & Wisniewski, H. M. (1985). Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathologica, 67, 289–295.PubMedCrossRefGoogle Scholar
  168. Saugstad, J. A., Marino, M. J., Folk, J. A., Hepler, J. R., & Conn, P. J. (1998). RGS4 inhibits signaling by group I metabotropic glutamate receptors. Journal of Neuroscience, 18, 905–913.PubMedGoogle Scholar
  169. Schenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J. L., & Giangrande, A. (2003). CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron, 38, 887–898.PubMedCrossRefGoogle Scholar
  170. Schütt, J., Falley, K., Richter, D., Kreienkamp, H. J., & Kindler, S. (2009). Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. Journal of Biological Chemistry, 284, 25479–25487.PubMedCrossRefGoogle Scholar
  171. Selby, L., Zhang, C., & Sun, Q. Q. (2007). Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neuroscience Letters, 412, 227–232.PubMedCrossRefGoogle Scholar
  172. Schaeffer, C., Bardoni, B., Mandel, J. L., Ehresmann, B., Ehresmann, C., Moine, H,. (2001). The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J. 20(17):4803–13.PubMedCrossRefGoogle Scholar
  173. Shang, Y., Wang, H., Mercaldo, V., Li, X., Chen, T., & Zhuo, M. (2009). Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. Journal of Neurochemistry, 111, 635–646.PubMedCrossRefGoogle Scholar
  174. Shi, S. H., Hayashi, Y., Petralia, R. S., Zaman, S. H., Wenthold, R. J., Svoboda, K., & Malinow, R. (1999). Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science, 284, 1811–1816.PubMedCrossRefGoogle Scholar
  175. Siomi, H., Siomi, M. C., Nussbaum, R. L., & Dreyfuss, G. (1993). The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell, 74, 291–298.PubMedCrossRefGoogle Scholar
  176. Siomi, M. C., Zhang, Y., Siomi, H., & Dreyfuss, G. (1996). Specific sequences in the fragile X syndrome protein FMR1 and the FXR proteins mediate their binding to 60S ribosomal subunits and the interactions among them. Molecular and Cellular Biology, 16, 3825–3832.PubMedGoogle Scholar
  177. Sittler, A., Devys, D., Weber, C., & Mandel, J. L. (1996). Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of fmr1 protein isoforms. Human Molecular Genetics, 5, 95–102.PubMedCrossRefGoogle Scholar
  178. Sjekloca, L., Konarev, P. V., Eccleston, J., Taylor, I. A., Svergun, D. I., & Pastore, A. (2009). A study of the ultrastructure of fragile-X-related proteins. Biochemical Journal, 419, 347–357.PubMedCrossRefGoogle Scholar
  179. Sofola, O. A., Jin, P., Qin, Y., Duan, R., Liu, H., de Haro, M., Nelson, D. L., & Botas, J. (2007). RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron, 55, 565–571.PubMedCrossRefGoogle Scholar
  180. Spencer, C. M., Alekseyenko, O., Hamilton, S. M., Thomas, A. M., Serysheva, E., Yuva-Paylor, L. A., & Paylor, R. (2011). Modifying behavioral phenotypes in Fmr1KO mice: Genetic background differences reveal autistic-like responses. Autism Research, 4, 40–56.PubMedCrossRefGoogle Scholar
  181. Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva-Paylor, L. A., & Paylor, R. (2005). Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes, Brain, and Behavior, 4, 420–430.PubMedCrossRefGoogle Scholar
  182. Spencer, C. M., Graham, D. F., Yuva-Paylor, L. A., Nelson, D. L., & Paylor, R. (2008). Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behavioral Neuroscience, 122, 710–715.PubMedCrossRefGoogle Scholar
  183. Sprangers, R., Groves, M. R., Sinning, I., & Sattler, M. (2003). High-resolution X-ray and NMR structures of the SMN Tudor domain: Conformational variation in the binding site for symmetrically dimethylated arginine residues. Journal of Molecular Biology, 327, 507–520.PubMedCrossRefGoogle Scholar
  184. Stefani, G., Fraser, C. E., Darnell, J. C., & Darnell, R. B. (2004). Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. Journal of Neuroscience, 24, 7272–7276.PubMedCrossRefGoogle Scholar
  185. Steward, O., & Schuman, E. M. (2003). Compartmentalized synthesis and degradation of proteins in neurons. Neuron, 40, 347–359.PubMedCrossRefGoogle Scholar
  186. Su, T., Fan, H. X., Jiang, T., Sun, W. W., Den, W. Y., Gao, M. M., Chen, S. Q., Zhao, Q. H., & Yi, Y. H. (2010). Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology (Berlin), 215(2):291–300.Google Scholar
  187. Sung, Y. J., Dolzhanskaya, N., Nolin, S. L., Brown, T., Currie, J. R., Denman, R. B,. (2003). The fragile X mental retardation protein FMRP binds elongation factor 1A mRNA and negatively regulates its translation in vivo. J Biol Chem. 278(18):15669–78. Epub 2003 Feb 19.PubMedCrossRefGoogle Scholar
  188. Suvrathan, A., Hoeffer, C. A., Wong, H., Klann, E., & Chattarji, S. (2010). Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America, 107, 11591–11596.PubMedCrossRefGoogle Scholar
  189. Tamanini, F., Van Unen, L., Bakker, C., Sacchi, N., Galjaard, H., Oostra, B. A., & Hoogeveen, A. T. (1999). Oligomerization properties of fragile-X mental-retardation protein (FMRP) and the fragile-X-related proteins FXR1P and FXR2P. Biochemical Journal, 343(Pt 3), 517–523.PubMedCrossRefGoogle Scholar
  190. Tassone, F., Beilina, A., Carosi, C., Albertosi, S., Bagni, C., Li, L., Glover, K., Bentley, D., & Hagerman, P. J. (2007). Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA, 13, 555–562.PubMedCrossRefGoogle Scholar
  191. Tassone, F., De Rubeis, S., Carosi, C., La Fata, G., Serpa, G., Raske, C., Willemsen, R., Hagerman, P. J., Bagni, C., (2011). Differential usage of transcriptional start sites and polyadenylation sites in FMR1 premutation alleles. Nucleic Acids Res, 2011. Aug: 39(14):6172–85. Epub 2011 Apr 7.PubMedCrossRefGoogle Scholar
  192. Tassone, F., Hagerman, R. J., Taylor, A. K., Gane, L. W., Godfrey, T. E., & Hagerman, P. J. (2000). Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile-X syndrome. American Journal of Human Genetics, 66, 6–15.PubMedCrossRefGoogle Scholar
  193. Tassone, F., Iwahashi, C., & Hagerman, P. J. (2004). FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biology, 1, 103–105.PubMedCrossRefGoogle Scholar
  194. Tervonen, T., Akerman, K., Oostra, B. A., & Castren, M. (2005). Rgs4 mRNA expression is decreased in the brain of Fmr1 knockout mouse. Brain Research. Molecular Brain Research, 133, 162–165.PubMedCrossRefGoogle Scholar
  195. Todd, P. K., & Mack, K. J. (2000). Sensory stimulation increases cortical expression of the fragile X mental retardation protein in vivo. Brain Research: Molecular Brain Research, 80, 17–25.PubMedCrossRefGoogle Scholar
  196. Tucker, B., Richards, R. I., & Lardelli, M. (2006). Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Human Molecular Genetics, 15, 3446–3458.PubMedCrossRefGoogle Scholar
  197. Valverde, R., Edwards, L., & Regan, L. (2008). Structure and function of KH domains. FEBS Journal, 275, 2712–2726.PubMedCrossRefGoogle Scholar
  198. Valverde, R., Pozdnyakova, I., Kajander, T., Venkatraman, J., & Regan, L. (2007). Fragile X mental retardation syndrome: Structure of the KH1-KH2 domains of fragile X mental retardation protein. Structure, 15, 1090–1098.PubMedCrossRefGoogle Scholar
  199. Van Dam, D., D’Hooge, R., Hauben, E., Reyniers, E., Gantois, I., Bakker, C. E., Oostra, B. A., Kooy, R. F., & De Deyn, P. P. (2000). Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behavioural Brain Research, 117, 127–136.PubMedCrossRefGoogle Scholar
  200. Vanderklish, P. W., & Edelman, G. M. (2002). Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America, 99, 1639–1644.PubMedCrossRefGoogle Scholar
  201. Ventura, R., Pascucci, T., Catania, M. V., Musumeci, S. A., & Puglisi-Allegra, S. (2004). Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: Involvement of dopamine in the medial prefrontal cortex. Behavioural Pharmacology, 15, 433–442.PubMedCrossRefGoogle Scholar
  202. Verheij, C., Bakker, C. E., de Graaff, E., Keulemans, J., Willemsen, R., Verkerk, A. J., Galjaard, H., Reuser, A. J., Hoogeveen, A. T., & Oostra, B. A. (1993). Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature, 363, 722–724.PubMedCrossRefGoogle Scholar
  203. Weiler, I. J., Irwin, S. A., Klintsova, A. Y., Spencer, C. M., Brazelton, A. D., Miyashiro, K., Comery, T. A., Patel, B., Eberwine, J., & Greenough, W. T. (1997). Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proceedings of the National Academy of Sciences of the United States of America, 94, 5395–5400.PubMedCrossRefGoogle Scholar
  204. Willemsen, R., Bontekoe, C., Tamanini, F., Galjaard, H., Hoogeveen, A., & Oostra, B. (1996). Association of FMRP with ribosomal precursor particles in the nucleolus. Biochemical and Biophysical Research Communications, 225, 27–33.PubMedCrossRefGoogle Scholar
  205. Westmark, C. J., Malter, J. S., (2007). FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5(3):e52.PubMedCrossRefGoogle Scholar
  206. Wohrle, D., Kotzot, D., Hirst, M. C., Manca, A., Korn, B., Schmidt, A., Barbi, G., Rott, H. D., Poustka, A., Davies, K. E., et al. (1992). A microdeletion of less than 250 kb, including the proximal part of the FMR-I gene and the fragile-X site, in a male with the clinical phenotype of fragile-X syndrome. American Journal of Human Genetics, 51, 299–306.PubMedGoogle Scholar
  207. Wolfer, D. P., & Lipp, H. P. (2000). Dissecting the behaviour of transgenic mice: Is it the mutation, the genetic background, or the environment? Experimental Physiology, 85, 627–634.PubMedCrossRefGoogle Scholar
  208. Xie, W., Dolzhanskaya, N., LaFauci, G., Dobkin, C., & Denman, R. B. (2009). Tissue and developmental regulation of fragile X mental retardation 1 exon 12 and 15 isoforms. Neurobiology of Disease, 35, 52–62.PubMedCrossRefGoogle Scholar
  209. Yan, Q. J., Asafo-Adjei, P. K., Arnold, H. M., Brown, R. E., & Bauchwitz, R. P. (2004). A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes, Brain, and Behavior, 3, 337–359.PubMedCrossRefGoogle Scholar
  210. Yun, S. H., & Trommer, B. L. (2011). Fragile X mice: Reduced long-term potentiation and N-methyl-D-aspartate receptor-mediated neurotransmission in dentate gyrus. Journal of Neuroscience Research, 89, 176–182.PubMedCrossRefGoogle Scholar
  211. Yuskaitis, C. J., Mines, M. A., King, M. K., Sweatt, J. D., Miller, C. A., & Jope, R. S. (2010). Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochemical Pharmacology, 79, 632–646.PubMedCrossRefGoogle Scholar
  212. Zalfa, F., Achsel, T., & Bagni, C. (2006). mRNPs, polysomes or granules: FMRP in neuronal protein synthesis. Current Opinion in Neurobiology, 16, 265–269.PubMedCrossRefGoogle Scholar
  213. Zalfa, F., Adinolfi, S., Napoli, I., Kuhn-Holsken, E., Urlaub, H., Achsel, T., Pastore, A., & Bagni, C. (2005). Fragile X mental retardation protein (FMRP) binds specifically to the brain cytoplasmic RNAs BC1/BC200 via a novel RNA-binding motif. Journal of Biological Chemistry, 280, 33403–33410.PubMedCrossRefGoogle Scholar
  214. Zalfa, F., & Bagni, C. (2005). Another view of the role of FMRP in translational regulation. Cellular and Molecular Life Sciences, 62, 251–252.PubMedCrossRefGoogle Scholar
  215. Zalfa, F., Eleuteri, B., Dickson, K. S., Mercaldo, V., De Rubeis, S., di Penta, A., Tabolacci, E., Chiurazzi, P., Neri, G., Grant, S. G., & Bagni, C. (2007). A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nature Neuroscience, 10, 578–587.PubMedCrossRefGoogle Scholar
  216. Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003). The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell, 112, 317–327.PubMedCrossRefGoogle Scholar
  217. Zang, J. B., Nosyreva, E. D., Spencer, C. M., Volk, L. J., Musunuru, K., Zhong, R., Stone, E. F., Yuva-Paylor, L. A., Huber, K. M., Paylor, R., Darnell, J. C., & Darnell, R. B. (2009). A mouse model of the human fragile X syndrome I304N mutation. PLoS Genetics, 5, e1000758.PubMedCrossRefGoogle Scholar
  218. Zarnescu, D. C., Shan, G., Warren, S. T., & Jin, P. (2005). Come FLY with us: Toward understanding fragile X syndrome. Genes, Brain, and Behavior, 4, 385–392.PubMedCrossRefGoogle Scholar
  219. Zeier, Z., Kumar, A., Bodhinathan, K., Feller, J. A., Foster, T. C., & Bloom, D. C. (2009). Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Therapy, 16, 1122–1129.PubMedCrossRefGoogle Scholar
  220. Zhang, Y. Q., Bailey, A. M., Matthies, H. J., Renden, R. B., Smith, M. A., Speese, S. D., Rubin, G. M., & Broadie, K. (2001). Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell, 107, 591–603.PubMedCrossRefGoogle Scholar
  221. Zhang, J., Fang, Z., Jud, C., Vansteensel, M. J., Kaasik, K., Lee, C. C., Albrecht, U., Tamanini, F., Meijer, J. H., Oostra, B. A., & Nelson, D. L. (2008). Fragile X-related proteins regulate mammalian circadian behavioral rhythms. American Journal of Human Genetics, 83, 43–52.PubMedCrossRefGoogle Scholar
  222. Zhang, J., Hou, L., Klann, E., & Nelson, D. L. (2009). Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. Journal of Neurophysiology, 101, 2572–2580.PubMedCrossRefGoogle Scholar
  223. Zhang, Y., O’Connor, J. P., Siomi, M. C., Srinivasan, S., Dutra, A., Nussbaum, R. L., & Dreyfuss, G. (1995). The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO Journal, 14, 5358–5366.PubMedGoogle Scholar
  224. Zhang, M., Wang, Q., & Huang, Y. (2007). Fragile X mental retardation protein FMRP and the RNA export factor NXF2 associate with and destabilize Nxf1 mRNA in neuronal cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 10057–10062.PubMedCrossRefGoogle Scholar
  225. Zhao, M. G., Toyoda, H., Ko, S. W., Ding, H. K., Wu, L. J., & Zhuo, M. (2005). Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. Journal of Neuroscience, 25, 7385–7392.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/WIen 2012

Authors and Affiliations

  • Silvia De Rubeis
    • 1
    • 2
  • Esperanza Fernández
    • 1
    • 2
  • Andrea Buzzi
    • 1
    • 2
  • Daniele Di Marino
    • 1
    • 2
  • Claudia Bagni
    • 1
    • 2
    • 3
    Email author
  1. 1.Center for Human GeneticsKatholieke Universiteit LeuvenLeuvenBelgium
  2. 2.Center for the Biology of DiseaseFlanders Institute for Biotechnology (VIB)LeuvenBelgium
  3. 3.Department of Experimental Medicine and Biochemical SciencesUniversity “Tor Vergata”RomeItaly

Personalised recommendations